NFE2L2 and colorectal cancer: Previously, we reported that E2 (10 mg/kg) inhibited the initiation of colorectal cancer (CRC) by activating Nrf2 in azoxymethane (AOM) plus DSS-treated male ICR mice, which showed more severe colitis-associated colon carcinogenesis compared to female mice [9].